NO883896L - Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin. - Google Patents

Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.

Info

Publication number
NO883896L
NO883896L NO88883896A NO883896A NO883896L NO 883896 L NO883896 L NO 883896L NO 88883896 A NO88883896 A NO 88883896A NO 883896 A NO883896 A NO 883896A NO 883896 L NO883896 L NO 883896L
Authority
NO
Norway
Prior art keywords
conjugates
cytkinermined
preparing
procedure
human
Prior art date
Application number
NO88883896A
Other languages
English (en)
Norwegian (no)
Other versions
NO883896D0 (no
Inventor
Peter Von Wussow
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO883896D0 publication Critical patent/NO883896D0/no
Publication of NO883896L publication Critical patent/NO883896L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07GCOMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G99/00Subject matter not provided for in other groups of this subclass
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO88883896A 1987-09-02 1988-09-01 Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin. NO883896L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH335787 1987-09-02

Publications (2)

Publication Number Publication Date
NO883896D0 NO883896D0 (no) 1988-09-01
NO883896L true NO883896L (no) 1989-03-03

Family

ID=4254228

Family Applications (1)

Application Number Title Priority Date Filing Date
NO88883896A NO883896L (no) 1987-09-02 1988-09-01 Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.

Country Status (15)

Country Link
EP (1) EP0305967B1 (ja)
JP (1) JPS6490200A (ja)
KR (1) KR890005137A (ja)
AT (1) ATE88900T1 (ja)
AU (1) AU627694B2 (ja)
DE (1) DE3880766D1 (ja)
DK (1) DK486588A (ja)
ES (1) ES2054753T3 (ja)
FI (1) FI884013A (ja)
IL (1) IL87621A0 (ja)
NO (1) NO883896L (ja)
NZ (1) NZ226005A (ja)
PH (1) PH26813A (ja)
PT (1) PT88385B (ja)
ZA (1) ZA886471B (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818055A1 (de) * 1988-05-27 1989-11-30 Biotest Pharma Gmbh Kombination aus humanen immunglobulinen und interleukin-2 zur bekaempfung von infektionskrankheiten
GB8820377D0 (en) * 1988-08-26 1988-09-28 Offord R E Chemical compounds
GB8820378D0 (en) * 1988-08-26 1988-09-28 Offord R E Chemical compounds
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
DE3839332A1 (de) * 1988-11-22 1990-05-23 Bayer Ag Verfahren zur herstellung von substituierten 2-chlorpyridinen
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
AU1193492A (en) * 1991-01-03 1992-08-17 Salk Institute For Biological Studies, The Mitotoxin for treatment of vascular injury
IE920366A1 (en) * 1991-02-04 1992-08-12 Univ Saskatchewan Vp6 encapsulated drug delivery
DE69213030D1 (de) * 1991-02-04 1996-09-26 Univ Saskatchewan Arzneistoffabgabe aus VP6-Kapseln
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
CA2218737C (en) * 1996-04-10 2003-12-16 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
IT1289608B1 (it) * 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
KR100863632B1 (ko) 2000-03-31 2008-10-15 퍼듀 리서치 파운데이션 리간드-면역원 접합체를 사용한 치료 방법
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
MXPA03008031A (es) 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
JP2004535202A (ja) 2001-07-17 2004-11-25 リサーチ ディベロップメント ファンデーション アポトーシス促進性蛋白質を含む治療剤
WO2003048334A2 (en) 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
JP2008502317A (ja) 2003-12-30 2008-01-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Il−7融合タンパク質
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
EP2421896A1 (en) 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
JP5879713B2 (ja) * 2010-12-09 2016-03-08 ソニー株式会社 画像処理装置、および画像処理方法、並びにプログラム
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
KR20150145260A (ko) 2013-04-19 2015-12-29 싸이튠 파마 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
DK486588D0 (da) 1988-09-01
ATE88900T1 (de) 1993-05-15
PT88385B (pt) 1992-10-30
ES2054753T3 (es) 1994-08-16
EP0305967A3 (en) 1990-01-31
NO883896D0 (no) 1988-09-01
IL87621A0 (en) 1989-01-31
KR890005137A (ko) 1989-05-13
EP0305967B1 (de) 1993-05-05
FI884013A (fi) 1989-03-03
DK486588A (da) 1989-03-03
EP0305967A2 (de) 1989-03-08
JPS6490200A (en) 1989-04-06
NZ226005A (en) 1990-10-26
PH26813A (en) 1992-11-05
AU627694B2 (en) 1992-09-03
DE3880766D1 (de) 1993-06-09
PT88385A (pt) 1989-07-31
AU2172588A (en) 1989-03-23
FI884013A0 (fi) 1988-08-31
ZA886471B (en) 1989-04-26

Similar Documents

Publication Publication Date Title
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
DE68929551D1 (de) Menschliche DNase
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
DE59101397D1 (de) O-glycosyliertes ifn-alpha.
NO943901D0 (no) Fremgangsmåter og preparater for behandling av sykdommer med interferon samtidig som bivirkninger reduseres
DK184186A (da) Terapeutisk praeparat til behandling af virussygdomme
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
NO931413L (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
NO891006D0 (no) Terapeutisk aktivt polypeptid og fremgangsmaate for dets fremstilling.
NO901396L (no) Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer.
EP0456842A4 (en) Medicinal application of m-csf
DK68388D0 (da) Anvendelse af oxochinazolinderivater til fremstilling af laegemidler til behandling af hyperurikaemi
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
NO933628L (no) Fremgangsmaate og blanding for behandling av Herpes-infeksjoner
NO890261D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.